Compare Immunovant Inc. Common Stock (IMVT) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Wells Fargo & Co — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Wells Fargo & Co trades at $82.13 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 39.7× Immunovant Inc. Common Stock's market cap, and Wells Fargo & Co pays a 2.44% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Wells Fargo & Co for 87 Days on average.
| IMVT | WFC | |
|---|---|---|
Market Cap | $6.25B | $248.06B |
Volume | 1,755,411 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $44.96 | $96.40 |
52-Week Low | $17.03 | $73.42 |
Typical Hold Time | 0 Days | 87 Days |
Enterprise Value | $5.35B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wells Fargo (WFC) trades at $80.26, down 1.53% with a bearish technical signal. The stock shows strong fundamentals with revenue growth to $83.7B in 2025 and improving net margins to 25.49%. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 earnings. Valuation metrics appear attractive with P/E of 11.67 and P/B of 1.47, trading below the consensus price target of $99.13.
WFC presents a compelling value opportunity with solid profitability and analyst support (46.7% buy ratings), though near-term headwinds include recent earnings misses and bearish technical indicators. The bank's improving credit profile and stable outlook support long-term growth potential, but investors should monitor interest rate sensitivity and execution on earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
